NMN in Europe

Regulatory status is time-sensitive. This page reflects the European regulatory record as understood on the last-reviewed date below and should be independently verified before any commercial decision. It is educational information, not legal advice.

The distinction this page is built around

In the European Union, NMN falls under the Novel Food framework (Regulation (EU) 2015/2283), which governs any food or food ingredient without a significant history of consumption in the EU before May 1997. This framework has several distinct stages, and conflating them is the single most common regulatory error made about NMN in Europe: a positive safety opinion from the European Food Safety Authority (EFSA) is a scientific risk assessment, not a market authorization. Authorization requires a separate European Commission implementing act adding the substance to the Union List of novel foods; until that act is published, the substance remains unauthorized for sale as a novel food in the EU regardless of what EFSA's opinion says.

NMN's EU history has two separate chapters

This is directly confirmed from the European Commission's own official novel food records, and it matters for an accurate picture: an earlier NMN novel food application was formally closed without success. The Commission's own "Decisions terminating the procedure" page lists Commission Implementing Decision of 31 March 2022 (C(2022) 1900 final), terminating the procedure for authorising the placing on the market within the Union of β-nicotinamide mononucleotide as a novel food — meaning that first application did not result in authorization and the procedure was closed.[1] A separate, later application — submitted August 2, 2023 by EffePharm (Shanghai) Co., Ltd., for synthetic β-NMN as a source of niacin at up to 300 mg/day — is the one that received EFSA's positive safety opinion in 2026, described below.[2] These are two distinct regulatory procedures for the same substance; the 2022 termination does not affect the current EffePharm application, and the current application's positive EFSA opinion does not retroactively revive the 2022 one.

The EFSA scientific opinion

EFSA's Panel on Nutrition, Novel Foods and Food Allergens adopted a scientific opinion on beta-nicotinamide mononucleotide (β-NMN) on March 4, 2026, published in the EFSA Journal on May 11, 2026.[2] The opinion concluded that intake of β-NMN up to 300 mg per day is safe for adults, excluding pregnant and lactating women, and assessed it as a bioavailable source of nicotinamide (vitamin B3) in the context of the EU's food supplements directive.[2] The opinion explicitly states that it "concerns only the risks that might be associated with consumption of the [novel food] under the proposed conditions of use and is not an assessment of the efficacy of the [novel food] with regard to any claimed benefit."[2]

What has not yet happened

As of this review, this hub directly checked the European Commission's own novel food procedure pages and found no Commission implementing act adding NMN to the Union List — the EffePharm application does not appear among terminated procedures (meaning it has not been rejected/closed), but it also does not appear as authorized. No NMN product is authorized for sale as a novel food ingredient anywhere in the EU on the EffePharm dossier's basis as of this review. This hub could not independently confirm the exact number of other pending NMN novel food applications from other companies against an official EU list, so that specific figure has been removed from this page rather than repeated from secondary sources.

United Kingdom

The UK operates its own, separate novel food regime (retained EU law administered by the Food Standards Agency and Food Standards Scotland following Brexit) rather than automatically following EU Commission decisions. This hub directly verified the UK's current status on the FSA's own regulated product applications database: an application for β-nicotinamide mononucleotide (application RP-2116, applicant EffePharm (Shanghai) Ltd.) is listed with status "In progress," currently at the "Risk assessment" stage of the FSA's three-stage process (risk assessment → risk management → authorisation).[3] NMN is therefore not yet authorized in the UK, and is at an earlier stage in the UK's own process than the equivalent EU application. The UK's status is legally independent of the EU's — a future EU authorization would not automatically extend to the UK, and vice versa.

Practical meaning for a reader in Europe today

As of this review's last-reviewed date, no NMN-containing product is authorized for sale in the EU as a novel food, and none is authorized in the UK. Products may nonetheless be sold in some markets in practice — enforcement posture varies by country and is a separate question from authorization status, and this hub did not conduct a country-by-country enforcement survey. A positive EFSA opinion is a meaningful signal that a specific applicant's dossier passed safety review, not evidence that NMN is currently authorized for general commercial sale in the EU.

Related reading

For the comparative picture across jurisdictions, see NMN Regulatory Status Around the World. For how this hub verifies regulatory claims, see Research Methodology.